Developmental funds for the next cycle are essential to our strategic plan to adopt new technology and acquire faculty expertise necessary to compliment our existing programs and advance cancer research. Moffitt proposes utilizing Developmental Funds in three categories as follows: 1) Targeted Faculty Recruitment ($200,000);2) Pilot Projects ($100,000) and 3) Development of New Shared Resources ($100,000). During the last funding period, Moffitt benefited from developmental funds and matching institutional funds in the areas of targeted faculty recruitment and pilot projects. Moffitt invested $18.5M in support of 51 new research members over the last funding cycle, including 4 supported by Developmental Funds. Recruitment packages include a portion of salary (protected time), start-up packages, capital investments for labs, and allocation of space. Moffitt also utilized Developmental Funds with additional institutional commitment to fund pilot proposals that demonstrated a high degree of collaboration and reflected new areas of research.

Public Health Relevance

Developmental Funds play an essential role in the continued growth of the Moffitt Cancer Center by providing resources for targeted recruitment, funding innovative collaborative pilot projects and developing new shared resources to support faculty needs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA076292-16
Application #
8613456
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-02-01
Budget End
2015-01-31
Support Year
16
Fiscal Year
2014
Total Cost
$214,119
Indirect Cost
$87,046
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
Tauro, Marilena; Shay, Gemma; Sansil, Samer S et al. (2017) Bone-Seeking Matrix Metalloproteinase-2 Inhibitors Prevent Bone Metastatic Breast Cancer Growth. Mol Cancer Ther 16:494-505
Davis, Stacy N; Christy, Shannon M; Chavarria, Enmanuel A et al. (2017) A randomized controlled trial of a multicomponent, targeted, low-literacy educational intervention compared with a nontargeted intervention to boost colorectal cancer screening with fecal immunochemical testing in community clinics. Cancer 123:1390-1400
Song, Jinming; Hussaini, Mohammad; Zhang, Hailing et al. (2017) Comparison of the Mutational Profiles of Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocytosis. Am J Clin Pathol 147:444-452
Strom, Tobin; Harrison, Louis B; Giuliano, Anna R et al. (2017) Tumour radiosensitivity is associated with immune activation in solid tumours. Eur J Cancer 84:304-314
Heit, Claire; Marshall, Stephanie; Singh, Surrendra et al. (2017) Catalase deletion promotes prediabetic phenotype in mice. Free Radic Biol Med 103:48-56
Eksioglu, E A; Chen, X; Heider, K-H et al. (2017) Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody BI 836858. Leukemia 31:2172-2180
Kamath, Vidya P; Torres-Roca, Javier F; Eschrich, Steven A (2017) Integrating Biological Covariates into Gene Expression-Based Predictors of Radiation Sensitivity. Int J Genomics 2017:6576840
Liu, Ying; Balagurunathan, Yoganand; Atwater, Thomas et al. (2017) Radiological Image Traits Predictive of Cancer Status in Pulmonary Nodules. Clin Cancer Res 23:1442-1449
Chen, Yi; Fisher, Kate J; Lloyd, Mark et al. (2017) Multiplexed Liquid Chromatography-Multiple Reaction Monitoring Mass Spectrometry Quantification of Cancer Signaling Proteins. Methods Mol Biol 1647:19-45
Extermann, Martine; Leeuwenburgh, Christiaan; Samiian, Laila et al. (2017) Impact of chemotherapy on medium-term physical function and activity of older breast cancer survivors, and associated biomarkers. J Geriatr Oncol 8:69-75

Showing the most recent 10 out of 1137 publications